Compare KEEL & PSNL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | KEEL | PSNL |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 1.7B |
| IPO Year | 2020 | 2019 |
| Metric | KEEL | PSNL |
|---|---|---|
| Price | $2.19 | $15.84 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 5 |
| Target Price | $6.45 | ★ $15.17 |
| AVG Volume (30 Days) | ★ 20.4M | 2.2M |
| Earning Date | 11-05-2026 | 11-03-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 33.58 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $229,276,000.00 | $69,648,000.00 |
| Revenue This Year | N/A | $21.10 |
| Revenue Next Year | N/A | $30.66 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 72.03 | N/A |
| 52 Week Low | $2.23 | $4.96 |
| 52 Week High | $7.37 | $18.89 |
| Indicator | KEEL | PSNL |
|---|---|---|
| Relative Strength Index (RSI) | 26.11 | 45.86 |
| Support Level | N/A | $15.51 |
| Resistance Level | $3.91 | $16.58 |
| Average True Range (ATR) | 0.18 | 0.33 |
| MACD | -0.08 | -0.03 |
| Stochastic Oscillator | 0.00 | 30.70 |
Keel Infrastructure Corp is a North American digital infrastructure and energy company that develops and owns data centers and energy infrastructure for high-performance computing workloads, including AI. The group has a pipeline of 2.2 gigawatts and established grid interconnections already in place. It delivers scalable infrastructure solutions in high-demand power markets across Pennsylvania and Washington in the United States, and Quebec in Canada. It has data campuses in Moses Lake, Panther Creek, Sharon, Sherbrooke, and Scrubgrass.
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. The company' products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions.